BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25287155)

  • 21. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; MacGowan AP
    J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
    Sader HS; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus - Insights from a tertiary care center, South India.
    Niveditha N; Sujatha S
    Braz J Infect Dis; 2015; 19(6):585-9. PubMed ID: 26361841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
    Patel N; Lubanski P; Ferro S; Bonafede M; Harrington S; Evans A; Stellrecht K; Lodise TP
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5141-4. PubMed ID: 19805558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
    J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].
    Gostev VV; Popenko LN; Chernen'kaia TV; Naumenko ZS; Voroshilova TM; Zakharova IuA; Khokhlova OE; Kruglov AN; Ershova MG; Angelova SN; Poletaeva ED; Molchanova IV; Sidorenko SV
    Antibiot Khimioter; 2013; 58(9-10):13-20. PubMed ID: 24738238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.
    Takesue Y; Nakajima K; Takahashi Y; Ichiki K; Ishihara M; Wada Y; Tsuchida T; Uchino M; Ikeuchi H
    J Infect Chemother; 2011 Feb; 17(1):52-7. PubMed ID: 20625789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China.
    Chang W; Ma X; Gao P; Lv X; Lu H; Chen F
    Indian J Med Microbiol; 2015; 33(2):262-6. PubMed ID: 25865979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study.
    Farrell DJ; Robbins M; Rhys-Williams W; Love WG
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1177-81. PubMed ID: 21149626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE; Fallon M; Moran JJ; Vanderloo JP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in vancomycin MIC among MRSA isolates by agar dilution and E test method.
    Tandel K; Praharaj AK; Kumar S
    Indian J Med Microbiol; 2012; 30(4):453-5. PubMed ID: 23183472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
    Hawser SP; Bouchillon SK; Hoban DJ; Dowzicky M; Babinchak T
    Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
    Sader HS; Becker HK; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.